CLR 3001

Drug Profile

CLR 3001

Alternative Names: CLR3001

Latest Information Update: 12 Feb 2016

Price : $50

At a glance

  • Originator Clera
  • Class Antidementias; Antidepressants; Small molecules
  • Mechanism of Action Dopamine receptor modulators; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cognition disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 12 Feb 2016 CLR 3001 is still in phase IIa trial for Cognition disorder in Canada (Clera pipeline, February 2016)
  • 21 Jan 2014 CLR 3001 is available for licensing as of 01 Jan 2014. http://www.clera.com
  • 01 Jan 2014 Discontinued - Phase-II for Major depressive disorder in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top